Last updated on November 2018

Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease

Brief description of study

PRECISION-HD1 is a Phase 1b/2a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of WVE-120101 in adult patients with early manifest Huntington's disease (HD) who carry a targeted single nucleotide polymorphism (SNP) rs362307 (SNP1).

Clinical Study Identifier: NCT03225833

Contact Investigators or Research Sites near you

Start Over

Mark Guttman, MD

Centre For Movement Disorders
Toronto, ON Canada
  Connect »

Grzegorz Witkowski, MD

Instytut Psychiatrii i Neurologii
Warsaw, Poland
  Connect »

Sylvain Chouinard, MD

Center Hospitalier de l'Universite de Montreal
Montreal, QC Canada
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.